Effects of high-flow nasal cannula oxygen therapy in bronchiectasis and hypercapnia: a retrospective observational study.
Bronchiectasis
High-flow nasal cannula
Noninvasive ventilation
Respiratory failure
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
01
02
2024
accepted:
24
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
2
5
2024
Statut:
epublish
Résumé
The effectiveness of high-flow nasal cannula (HFNC) therapy in patients with bronchiectasis experiencing hypercapnia remains unclear. Our aim was to retrospectively analyze the short-term outcomes of HFNC therapy in such patients, and to further explore the predictors of HFNC treatment failure in this particular patient population. A retrospective review was conducted on patients with bronchiectasis who received HFNC (n = 70) for hypercapnia (arterial partial pressure of carbon dioxide, PaCO In the study population, 30% of patients presented with acidemia (arterial pH < 7.35) at baseline. Within 24 h of HFNC treatment, there was a significant reduction in PaCO In patients with bronchiectasis and hypercapnia, HFNC as an initial respiratory support can effectively reduce PaCO
Sections du résumé
BACKGROUND
BACKGROUND
The effectiveness of high-flow nasal cannula (HFNC) therapy in patients with bronchiectasis experiencing hypercapnia remains unclear. Our aim was to retrospectively analyze the short-term outcomes of HFNC therapy in such patients, and to further explore the predictors of HFNC treatment failure in this particular patient population.
METHODS
METHODS
A retrospective review was conducted on patients with bronchiectasis who received HFNC (n = 70) for hypercapnia (arterial partial pressure of carbon dioxide, PaCO
RESULTS
RESULTS
In the study population, 30% of patients presented with acidemia (arterial pH < 7.35) at baseline. Within 24 h of HFNC treatment, there was a significant reduction in PaCO
CONCLUSIONS
CONCLUSIONS
In patients with bronchiectasis and hypercapnia, HFNC as an initial respiratory support can effectively reduce PaCO
Identifiants
pubmed: 38698379
doi: 10.1186/s12890-024-03037-2
pii: 10.1186/s12890-024-03037-2
doi:
Substances chimiques
Carbon Dioxide
142M471B3J
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
217Informations de copyright
© 2024. The Author(s).
Références
O’Donnell AE. Bronchiectasis - A clinical review. N Engl J Med. 2022;387(6):533–45.
doi: 10.1056/NEJMra2202819
pubmed: 35947710
Goeminne PC, Nawrot TS, Ruttens D, Seys SDupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med. 2014;108(2):287–96.
doi: 10.1016/j.rmed.2013.12.015
pubmed: 24445062
Phua J, Ang YL, See KC, Mukhopadhyay A, Santiago EA, Dela Pena EG, et al. Noninvasive and invasive ventilation in acute respiratory failure associated with bronchiectasis. Intensive Care Med. 2010;36(4):638–47.
doi: 10.1007/s00134-009-1743-6
pubmed: 20052456
Dupont M, Gacouin A, Lena H, Lavoué S, Brinchault G, Delaval P, et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest. 2004;125(5):1815–20.
doi: 10.1378/chest.125.5.1815
pubmed: 15136395
Alzeer AH, Masood M, Basha SJShaik SA. Survival of bronchiectatic patients with respiratory failure in ICU. BMC Pulm Med. 2007;7:17.
doi: 10.1186/1471-2466-7-17
pubmed: 18070340
pmcid: 2222020
Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J, 2017. 50(2).
Comellini V, Pacilli AMGNava S. Benefits of non-invasive ventilation in acute hypercapnic respiratory failure. Respirology. 2019;24(4):308–17.
doi: 10.1111/resp.13469
pubmed: 30636373
Munshi L, Mancebo JBrochard LJ. Noninvasive respiratory support for adults with Acute Respiratory failure. N Engl J Med. 2022;387(18):1688–98.
doi: 10.1056/NEJMra2204556
pubmed: 36322846
Oczkowski S, Ergan B, Bos L, Chatwin M, Ferrer M, Gregoretti C et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J, 2022. 59(4).
Goligher ECSlutsky AS. Not just Oxygen? Mechanisms of Benefit from High-Flow Nasal Cannula in Hypoxemic Respiratory failure. Am J Respir Crit Care Med. 2017;195(9):1128–31.
doi: 10.1164/rccm.201701-0006ED
Crimi C, Noto A, Cortegiani A, Campisi R, Heffler E, Gregoretti C, et al. High Flow Nasal Therapy Use in patients with Acute Exacerbation of COPD and Bronchiectasis: a feasibility study. Copd. 2020;17(2):184–90.
doi: 10.1080/15412555.2020.1728736
pubmed: 32088995
Cuquemelle E, Pham T, Papon JF, Louis B, Danin PEBrochard L. Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. Respir Care. 2012;57(10):1571–7.
doi: 10.4187/respcare.01681
pubmed: 22417569
Lee MK, Choi J, Park B, Kim B, Lee SJ, Kim SH, et al. High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. Clin Respir J. 2018;12(6):2046–56.
doi: 10.1111/crj.12772
pubmed: 29392846
Cortegiani A, Longhini F, Madotto F, Groff P, Scala R, Crimi C, et al. High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized trial. Crit Care. 2020;24(1):692.
doi: 10.1186/s13054-020-03409-0
pubmed: 33317579
pmcid: 7734463
Sun J, Li Y, Ling B, Zhu Q, Hu Y, Tan D, et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1229–37.
doi: 10.2147/COPD.S206567
pubmed: 31239658
pmcid: 6556470
Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.
doi: 10.1136/thoraxjnl-2018-212463
pubmed: 30545985
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
doi: 10.1086/511159
pubmed: 17278083
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4–131.
doi: 10.1002/ejhf.2333
pubmed: 35083827
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.
doi: 10.1183/09031936.00080312
pubmed: 22743675
pmcid: 3786581
Gregoretti C, Pisani L, Cortegiani ARanieri VM. Noninvasive ventilation in critically ill patients. Crit Care Clin. 2015;31(3):435–57.
doi: 10.1016/j.ccc.2015.03.002
pubmed: 26118914
Pisani L, Astuto M, Prediletto ILonghini F. High flow through nasal cannula in exacerbated COPD patients: a systematic review. Pulmonology. 2019;25(6):348–54.
doi: 10.1016/j.pulmoe.2019.08.001
pubmed: 31591056
Simioli F, Fiorentino G, Cauteruccio R, Coppola A, Imitazione P, Marotta A et al. Long-term high Flow Nasal Cannula Therapy in primary and secondary Bronchiectasis. Healthc (Basel), 2023. 11(9).
Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med. 2010;104(4):525–33.
doi: 10.1016/j.rmed.2009.12.016
pubmed: 20144858
Martinez-García M, Olveira C, Girón R, García-Clemente M, Máiz-Carro L, Sibila O et al. Peripheral neutrophil-to-lymphocyte ratio in Bronchiectasis: a marker of Disease Severity. Biomolecules, 2022. 12(10).
Zinellu A, Zinellu E, Mangoni AA, Pau MC, Carru C, Pirina P et al. Clinical significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute exacerbations of COPD: present and future. Eur Respir Rev, 2022. 31(166).
Enersen CC, Egelund GB, Petersen PT, Andersen S, Ravn P, Rohde G, et al. The ratio of neutrophil-to-lymphocyte and platelet-to-lymphocyte and association with mortality in community-acquired pneumonia: a derivation-validation cohort study. Infection. 2023;51(5):1339–47.
doi: 10.1007/s15010-023-01992-2
pubmed: 36763284
Huang Z, Fu Z, Huang WHuang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis. Am J Emerg Med. 2020;38(3):641–7.
doi: 10.1016/j.ajem.2019.10.023
pubmed: 31785981
Steer J, Norman EM, Afolabi OA, Gibson GJBourke SC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67(2):117–21.
doi: 10.1136/thoraxjnl-2011-200332
pubmed: 21896712
Mauri T, Alban L, Turrini C, Cambiaghi B, Carlesso E, Taccone P, et al. Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates. Intensive Care Med. 2017;43(10):1453–63.
doi: 10.1007/s00134-017-4890-1
pubmed: 28762180
Delorme M, Bouchard PA, Simon M, Simard SLellouche F. Effects of High-Flow Nasal Cannula on the work of breathing in patients recovering from Acute Respiratory failure. Crit Care Med. 2017;45(12):1981–8.
doi: 10.1097/CCM.0000000000002693
pubmed: 28857852